Stoke Therapeutics, Inc. Earnings Per Share (Basic)
Stoke Therapeutics, Inc. (STOK) reported Earnings Per Share (Basic) of -$0.93 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-03
- Stoke Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.93.
- Stoke Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.79, a 140.51% decline year-over-year.
- Stoke Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.93.
- Stoke Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.65.
- Stoke Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$0.12.
- Stoke Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.65.
- Stoke Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$2.38.
- Stoke Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$2.60.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.93 10-Q · filed 2026-08-03 | -$1.73 10-Q · filed 2026-08-03 | -$2.66 derived: net income ÷ weighted average shares · filed 2026-08-03 | -$3.33 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2026-03-31 | -$0.79 10-Q · filed 2026-05-07 | -$1.73 derived: net income ÷ weighted average shares · filed 2026-08-03 | -$2.39 derived: net income ÷ weighted average shares · filed 2026-08-03 | -$2.81 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2025-12-31 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.60 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-08-03 | -$0.12 10-K · filed 2026-03-16 |
| 2025-09-30 | -$0.65 10-Q · filed 2025-11-04 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.88 10-Q · filed 2025-11-04 | $0.70 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2025-06-30 | -$0.40 10-Q · filed 2026-08-03 | $1.54 10-Q · filed 2026-08-03 | $1.37 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.91 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2025-03-31 | $1.95 10-Q · filed 2026-05-07 | $1.78 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.33 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.89 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2024-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.65 10-K · filed 2026-03-16 |
| 2024-09-30 | -$0.47 10-Q · filed 2025-11-04 | -$0.93 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$1.48 10-Q · filed 2025-11-04 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-04-22 |
| 2024-06-30 | -$0.46 10-Q · filed 2025-08-12 | -$1.02 10-Q · filed 2025-08-12 | -$1.61 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-04-22 |
| 2024-03-31 | -$0.57 10-Q · filed 2025-05-13 | -$1.17 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.72 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$2.42 derived: net income ÷ weighted average shares · filed 2026-04-22 |
| 2023-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.85 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$2.38 10-K · filed 2025-03-18 |
| 2023-09-30 | -$0.55 10-Q · filed 2024-11-05 | -$1.25 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.78 10-Q · filed 2024-11-05 | -$2.43 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-06-30 | -$0.69 10-Q · filed 2024-08-07 | -$1.23 10-Q · filed 2024-08-07 | -$1.88 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.54 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-03-31 | -$0.53 10-Q · filed 2024-05-06 | -$1.18 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.84 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.46 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2022-12-31 | -$0.65 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$1.31 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$1.94 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$2.60 10-K · filed 2024-03-25 |
| 2022-09-30 | -$0.66 10-Q · filed 2023-11-07 | -$1.29 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.95 10-Q · filed 2023-11-07 | -$2.61 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-06-30 | -$0.63 10-Q · filed 2023-08-07 | -$1.29 10-Q · filed 2023-08-07 | -$1.95 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.56 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-03-31 | -$0.66 10-Q · filed 2023-05-04 | -$1.32 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.94 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.54 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2021-12-31 | -$0.66 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$1.28 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$1.88 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$2.34 10-K · filed 2023-03-06 |
| 2021-09-30 | -$0.61 10-Q · filed 2022-11-14 | -$1.21 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.67 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$0.60 10-Q · filed 2022-08-08 | -$1.06 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |